» Articles » PMID: 34097208

Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study

Overview
Journal AIDS Behav
Date 2021 Jun 7
PMID 34097208
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Accurate reporting of antiretroviral therapy (ART) uptake is crucial for measuring the success of epidemic control. Programs without linked electronic medical records are susceptible to duplicating ART initiation events. We assessed the prevalence of undisclosed ART use at the time of treatment initiation and explored its correlates among people presenting to public ambulatory clinics in South Africa. Data were analyzed from the community-based delivery of ART (DO ART) clinical trial, which recruited people living with HIV who presented for ART initiation at two clinics in rural South Africa. We collected data on socioeconomic factors, clinical factors, and collected blood as part of study screening procedures. We estimated the proportion of individuals presenting for ART initiation with viral load suppression (< 20 copies/mL) and fitted regression models to identify social and clinical correlates of non-disclosure of ART use. We also explored clinical and national databases to identify records of ART use. Finally, to confirm surreptitious ART use, we measured tenofovir (TDF) and emtricitabine (FTC) levels in dried blood spots. A total of 193 people were screened at the two clinics. Approximately 60% (n = 114) were female, 40% (n = 78) reported a prior HIV test, 23% (n = 44) had disclosed to a partner, and 31% (n = 61) had a partner with HIV. We found that 32% (n = 62) of individuals presenting for ART initiation or re-initiation had an undetectable viral load. In multivariable regression models, female sex (AOR 2.16, 95% CI 1.08-4.30), having a prior HIV test and having disclosed their HIV status (AOR 2.48, 95% CI 1.13-5.46), and having a partner with HIV (AOR 1.94, 95% CI 0.95-3.96) were associated with having an undetectable viral load. In records we reviewed, we found evidence of ART use from either clinical or laboratory databases in 68% (42/62) and detected either TDF or FTC in 60% (37/62) of individuals with an undetectable viral load. Undisclosed ART use was present in approximately one in three individuals presenting for ART initiation or re-initiation at ambulatory HIV clinics in South Africa. These results have important implications for ART resource use and planning in the region. A better understanding of reasons for non-disclosure of ART at primary health care clinics in such settings is needed.

Citing Articles

Can routine antenatal data be used to assess HIV antiretroviral therapy coverage among pregnant women? Evaluating the validity of different data sources in the Western Cape, South Africa.

Jacob N, Rice B, Heekes A, Johnson L, Brinkmann S, Kufa T PLoS One. 2024; 19(4):e0291844.

PMID: 38635753 PMC: 11025901. DOI: 10.1371/journal.pone.0291844.


The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms.

van den Berg K, Murphy E, Maartens G, Louw V, Grebe E Vox Sang. 2024; 119(6):581-589.

PMID: 38622931 PMC: 11821652. DOI: 10.1111/vox.13627.


Preferences for services in a patient's first six months on antiretroviral therapy for HIV in South Africa and Zambia (PREFER): research protocol for a prospective observational cohort study.

Maskew M, Ntjikelane V, Juntunen A, Scott N, Benade M, Sande L Gates Open Res. 2024; 7:119.

PMID: 38343769 PMC: 10858017. DOI: 10.12688/gatesopenres.14682.2.


Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.

Asare K, Lewis L, van der Molen J, Sookrajh Y, Khubone T, Moodley P Open Forum Infect Dis. 2023; 10(12):ofad583.

PMID: 38045558 PMC: 10691652. DOI: 10.1093/ofid/ofad583.


Prior exposure to antiretroviral therapy among adult patients presenting for HIV treatment initiation or reinitiation in sub-Saharan Africa: a systematic review.

Benade M, Maskew M, Juntunen A, Flynn D, Rosen S BMJ Open. 2023; 13(11):e071283.

PMID: 37984944 PMC: 10660894. DOI: 10.1136/bmjopen-2022-071283.


References
1.
Barnabas R, Szpiro A, van Rooyen H, Asiimwe S, Pillay D, Ware N . Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. Lancet Glob Health. 2020; 8(10):e1305-e1315. PMC: 7527697. DOI: 10.1016/S2214-109X(20)30313-2. View

2.
Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K . Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defic Syndr. 2011; 58(2):141-7. DOI: 10.1097/QAI.0b013e31822866a2. View

3.
Truong W, Schafer J, Short W . Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. P T. 2015; 40(1):44-55. PMC: 4296592. View

4.
Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N . A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014; 17:18908. PMC: 4005043. DOI: 10.7448/IAS.17.1.18908. View

5.
Kharsany A, Cawood C, Khanyile D, Grobler A, McKinnon L, Samsunder N . Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. BMC Public Health. 2015; 15:1149. PMC: 4654918. DOI: 10.1186/s12889-015-2179-2. View